title: High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas.
abstract: Peripheral T cell lymphomas (PTCL) have a poorer prognosis after conventional treatment than do high-grade B cell lymphomas. The place for high-dose therapy (HDT) with autologous stem cell support in these patients is still not clear. Forty patients, 10 women and 30 men, median age 41.5 years (range 16-61) with PTCL were treated with HDT and autologous stem cell support at The Norwegian Radium Hospital, Oslo, Norway and The University Hospital, Uppsala, Sweden, between February 1990 and September 1999. The histologic subtypes were: PTCL unspecified, 20 patients; intestinal, two patients; angioimmunoblastic (AILD), two patients; angiocentric, two patients and anaplastic large cell lymphoma (ALCL), 14 patients. All patients had chemosensitive disease and had received anthracycline-containing regimens prior to transplantation. At the time of HDT, 17 patients were in first PR or CR and 23 were in second or third PR or CR. Conditioning regimens were BEAM in 15 patients, BEAC in 14 patients, cyclophosphamide and total body irradiation (TBI) in eight patients, BEAC, without etoposide and TBI in one patient and mitoxantrone and melphalan in two patients. There were three (7.5%) treatment-related deaths. The estimated overall survival (OS) at 3 years was 58%, the event-free survival (EFS) 48% and the relapse-free survival (RFS) 56%, with a median follow-up of 36 months (range 7-100) for surviving patients. The patients with ALCL tended to have a better prognosis compared to those with other PTCL subtypes, OS 79% vs 44%, respectively. In conclusion, patients with chemosensitive PTCL who are failing to achieve CR with first-line chemotherapy or are in relapse can successfully be treated with HDT and autologous stem cell support.
authors.affiliation: Department of Oncology and Pathology, The Norwegian Radium Hospital, 0310 Oslo, Norway.
authors.forename: A K
authors.initials: AK
authors.lastname: Blystad
authors.forename: G
authors.initials: G
authors.lastname: Enblad
authors.forename: S
authors.initials: S
authors.lastname: Kvaløy
authors.forename: A
authors.initials: A
authors.lastname: Berglund
authors.forename: J
authors.initials: J
authors.lastname: Delabie
authors.forename: H
authors.initials: H
authors.lastname: Holte
authors.forename: K
authors.initials: K
authors.lastname: Carlson
authors.forename: G
authors.initials: G
authors.lastname: Kvalheim
authors.forename: M
authors.initials: M
authors.lastname: Bengtsson
authors.forename: H
authors.initials: H
authors.lastname: Hagberg
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D013548:Sweden; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous / Q000379:methods / Q000401:mortality